NASDAQ:ENLV Enlivex Therapeutics (ENLV) Stock Price, News & Analysis $0.86 +0.01 (+0.58%) Closing price 04/17/2025 03:55 PM EasternExtended Trading$0.86 0.00 (0.00%) As of 04/17/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enlivex Therapeutics Stock (NASDAQ:ENLV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enlivex Therapeutics alerts:Sign Up Key Stats Today's Range$0.84▼$0.9150-Day Range$0.86▼$1.2252-Week Range$0.81▼$1.84Volume12,233 shsAverage Volume131,659 shsMarket Capitalization$18.52 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewEnlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Read More… Enlivex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreENLV MarketRank™: Enlivex Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 586th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingEnlivex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnlivex Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Enlivex Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Enlivex Therapeutics are expected to grow in the coming year, from ($0.70) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enlivex Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.56% of the float of Enlivex Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently decreased by 17.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.56% of the float of Enlivex Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently decreased by 17.86%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentEnlivex Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Enlivex Therapeutics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.02% of the stock of Enlivex Therapeutics is held by institutions.Read more about Enlivex Therapeutics' insider trading history. Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ENLV Stock News HeadlinesIs Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?April 7, 2025 | finance.yahoo.comEnlivex Therapeutics doses first patient in Phase I trial of AllocetraApril 4, 2025 | markets.businessinsider.comMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so. Musk has been quietly creating one of the most ambitious AI ventures in history.April 18, 2025 | Behind the Markets (Ad)Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisApril 3, 2025 | globenewswire.comEnlivex Therapeutics Releases 2024 Financial StatementsMarch 31, 2025 | tipranks.comEnlivex Therapeutics price target raised to $7 from $6 at H.C. WainwrightMarch 24, 2025 | markets.businessinsider.comEnlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for OsteoarthritisMarch 19, 2025 | nasdaq.comEnlivex Therapeutics receives notice of allowance for Chinese patentMarch 17, 2025 | markets.businessinsider.comSee More Headlines ENLV Stock Analysis - Frequently Asked Questions How have ENLV shares performed this year? Enlivex Therapeutics' stock was trading at $1.17 at the start of the year. Since then, ENLV stock has decreased by 26.1% and is now trading at $0.8650. View the best growth stocks for 2025 here. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) posted its quarterly earnings data on Monday, March, 31st. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.07. How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), CrowdStrike (CRWD), Adobe (ADBE) and Meta Platforms (META). Company Calendar Last Earnings3/31/2025Today4/18/2025Next Earnings (Estimated)6/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENLV CIK1596812 Webwww.enlivex.com Phone(728) 662-3301Fax972-2620-8070Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,056.1%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.57% Return on Assets-58.45% Debt Debt-to-Equity RatioN/A Current Ratio9.71 Quick Ratio9.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book0.53Miscellaneous Outstanding Shares21,406,000Free Float18,777,000Market Cap$18.52 million OptionableOptionable Beta0.85 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ENLV) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.